EP1706097A2 - Medicament destine a etre administre a des animaux par voie topique - Google Patents

Medicament destine a etre administre a des animaux par voie topique

Info

Publication number
EP1706097A2
EP1706097A2 EP05700727A EP05700727A EP1706097A2 EP 1706097 A2 EP1706097 A2 EP 1706097A2 EP 05700727 A EP05700727 A EP 05700727A EP 05700727 A EP05700727 A EP 05700727A EP 1706097 A2 EP1706097 A2 EP 1706097A2
Authority
EP
European Patent Office
Prior art keywords
loq
acid
application
animals
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05700727A
Other languages
German (de)
English (en)
Inventor
Dirk Mertin
Gerald Beddies
Iris Heep
Nikolaus Kowollik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1706097A2 publication Critical patent/EP1706097A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • the invention relates to pharmaceutical preparations which are applied to the fur or skin of animals and then subsequently taken up orally by them.
  • the oral application of pharmaceuticals to animals depends on the taste properties of the active ingredient and the formulation.
  • active ingredients such as Fluoroquinolones and praziquantel are very difficult to handle in pets.
  • palatable oral dosage forms which are voluntarily taken up by the pet from the hand of the pet owner or from a feed bowl.
  • the pet owner usually applies oral medication in one of the following ways: In the so-called "poke down” method, the medication is placed on the base of the tongue and then the mouth is closed. The head is moved into the normal position and the throat is gently massaged, until the drug is swallowed, sometimes small amounts of liquid are given to make it easier to swallow.
  • the drug is hidden in a piece of food and then administered.
  • This method is unsuitable if the active ingredient has to be administered on an empty stomach or strong bitter taste of the food overlaps the taste of the food, less often the medicinal form is crushed and sprinkled over food or dissolved in water.
  • the invention therefore relates to:
  • a pharmaceutical preparation for use on animals which is applied to the fur or skin of the animal and is then taken up orally by the animal.
  • the invention further relates to:
  • a method for the application of active pharmaceutical ingredients in animals in which a pharmaceutical preparation containing the corresponding active ingredient is topically applied to the animal and the animal then takes the applied pharmaceutical preparation orally.
  • suitable preparations according to the invention are all those which can be applied topically and which are also acceptable for oral administration.
  • the following may be mentioned as such: liquid, semi-liquid or pasty, and solid preparations. Liquid preparations are particularly preferred.
  • the topical application happens e.g. in the form of diving (dip), spraying (spray), bathing, washing, pouring on (pour-on and spot-on) and rubbing in.
  • Suitable preparations are solutions, emulsions and suspensions.
  • Solutions for topical application are dripped on, spread on, rubbed in, sprayed on, sprayed on or applied by dipping (dipping, bathing or washing).
  • the topical application of the preparations according to the invention is preferably carried out on the trunk, in particular, for. B. on the back or on the flanks of the animals.
  • Solutions are prepared by dissolving the active ingredient in a suitable solvent and possibly adding additives such as solubilizers, acids, bases, buffer salts, antioxidants, preservatives.
  • solvents water, alkanols, glycols, polyethylene glycols, polypropylene glycols, glycerol, aromatic alcohols such as benzyl alcohol, phenylethanol, phenoxyethanol, esters such as ethyl acetate, butyl acetate, benzyl benzoate, ethers such as alkylene glycol alkyl ethers such as dipropylene glycol monomethyl ether, diethylene glycol such as butylene glycol Acetone, methyl ethyl ketone, aromatic and / or aliphatic hydrocarbons, vegetable or synthetic oils, such as medium-chain triglycerides or propylene glycol esters with medium-chain fatty acids, DMF, dimethylacetamide, N-methylpyrrohdon, 2-dimethyl-4-oxy-methylene-l, 3-dimoxolane and mixtures of the aforementioned solvents. Vegetable or synthetic oils and their mixtures with the solvents mentioned are examples of the solvents mentioned
  • solubilizers solvents which promote the dissolution of the active ingredient in the main solvent or prevent its precipitation.
  • solvents which promote the dissolution of the active ingredient in the main solvent or prevent its precipitation.
  • examples are polyvinylpyrrolidone, polyoxyethylated castor oil, polyoxyethylated sorbitan esters.
  • Preservatives are, for example, benzyl alcohol, n-butanol, trichlorobutanol, p-hydroxybenzoic acid ester, benzoic acid, propionic acid, sorbic acid.
  • the solutions can be applied directly. Concentrates are applied to the application concentration after prior dilution.
  • Thickeners are: inorganic thickeners such as bentomets, colloidal silica, aluminum monostearate, organic thickeners such as cellulose derivatives, xanthan, carageenan, algmate, starch, gelatin, polyvinyl alcohols and their copolymers, acrylates and methacrylates.
  • inorganic thickeners such as bentomets, colloidal silica, aluminum monostearate
  • organic thickeners such as cellulose derivatives, xanthan, carageenan, algmate, starch, gelatin, polyvinyl alcohols and their copolymers, acrylates and methacrylates.
  • Dyes are all dyes approved for use on animals, which can be dissolved or suspended.
  • Antioxidants are sulfites or metabisulfites such as sodium sulfite, potassium metabisulfate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, tocopherol.
  • Light stabilizers are e.g. Substances from the class of benzophenones or novantisolic acid.
  • Adhesives are e.g. Cellulose derivatives, xanthan, carageenan, alginates, starch, gelatin, polyvinyl alcohols and their copolymers, acrylates and methacrylates.
  • Emulsions are either water in oil or oil in water.
  • hydrophobic phase paraffin oils, silicone oils, natural vegetable oils such as sesame oil, almond oil, castor oil, synthetic triglycerides such as caprylic / capric acid biglyce ⁇ d, Triglyceride mixture with vegetable fatty acid of chain length Cg. ⁇ 2 or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated fatty acids, which may also contain hydroxyl groups, mono- and diglycerides of C3 / C1 Q fatty acids.
  • Fatty acid esters such as ethyl stearate, di-n-butyryl adipate, lauric acid hexyl ester, dipropylene glycol pelargonate, esters of a branched fatty acid of medium chain length with saturated fatty alcohols of chain length Ci g-Ci g, isopropyl myristate, isopropyl palmitate, caprylic / capric acid esters of saturated fatty alcohol ⁇ C j g, isopropyl stearate, oleic acid oleyl ester, oleic acid decyl ester, ethyl oleate, lactic acid ethyl ester, waxy fatty acid esters such as artificial duck oil gland fat, dibutyl phthalate, adipic acid diisopropyl ester, the latter related ester mixtures and others
  • Fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol, oleyl alcohol.
  • Fatty acids such as Oleic acid and its mixtures.
  • hydrophilic phase The following are mentioned as the hydrophilic phase:
  • Alcohols such as e.g. Propylene glycol, glycerin, sorbitol and their mixtures.
  • nonionic surfactants e.g. polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ether;
  • ampholytic surfactants such as di-Na-N-lauryl- ⁇ -iminodipropionate or lecithin;
  • anionic surfactants such as sodium lauryl sulfate, fatty alcohol ether sulfates, mono / dialkyl polyglycol ether orthophosphoric acid ester monoethanolamine salt;
  • cationic surfactants such as cetyltrimethylammonium chloride.
  • auxiliaries that may be mentioned are: viscosity-increasing and emulsion-stabilizing substances such as carboxymethyl cellulose, methyl cellulose and other cellulose and starch derivatives, polyacrylates, alginates, gelatin, gum arabic, polyvinyl pyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycols, waxes , colloidal silica or mixtures of the listed substances.
  • viscosity-increasing and emulsion-stabilizing substances such as carboxymethyl cellulose, methyl cellulose and other cellulose and starch derivatives, polyacrylates, alginates, gelatin, gum arabic, polyvinyl pyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycols, waxes , colloidal silica or mixtures of the listed substances.
  • Suspensions are prepared by suspending the active ingredient in a carrier liquid, optionally with the addition of other auxiliaries such as wetting agents, dyes, preservatives, antioxidants and light stabilizers. All homogeneous solvents and solvent mixtures may be mentioned as carrier liquids.
  • the surfactants specified above may be mentioned as wetting agents (dispersants).
  • the preparations according to the invention must both meet all the conditions of a topical pharmaceutical preparation and be suitable for oral ingestion.
  • the preparation applied to the fur should adhere there.
  • a certain consistency is desirable, as z. B. have the examples of the invention.
  • the viscosity of the preparations according to the invention is therefore preferably 1 to 1000 mPa * s, particularly preferably 10 to 500 mPa * s. If the viscosity is too low, there is a risk that the formulation will drip off the fur. Highly viscous formulations, however, are difficult to apply. In addition, highly viscous preparations often adhere insufficiently to the fur and fall off or are shaken off before they can be taken up by the animal.
  • a good spreadability of the preparation is also desirable, so that it can also be used on a location of the coat which is difficult to clean.
  • a good spread also leads to a distribution of the preparation over a larger area of the fur.
  • the animal needs more time to take up the applied amount of active ingredient orally, which slows down the flooding in the body and increases the dwell time and thus the duration of action.
  • This therapeutically desirable extension of the residence time in the body could be shown by kinetic studies (see Figure 1 and Figure 2).
  • the examples according to the invention have good spreadability.
  • spot-on formulations in which small volumes - usually less than 10 ml, preferably 5 ml or less - of pharmaceuticals are topically administered to the animal are particularly preferred.
  • the agent then spreads over the surface of the animal.
  • the preparations according to the invention are preferably used in animals which have a cleaning reflex or cleaning behavior which favors absorption.
  • the preparations are used particularly in mammals, e.g. Cats, dogs, rabbits, rabbits, guinea pigs, hamsters, mice and rats but also used in birds. Use in rabbits and especially cats is particularly preferred.
  • Examples include:
  • 4,704,459 (Toyama) include: Benofloxacin, Binfloxacin, Cinoxacin, Ciprofloxacin, Danofloxacin, Difloxacin, Enoxacin, Enrofloxacin, Fleroxacin, Gatifloxacin, Levofloxacin, Loxofloxacin, Ibox Moxifloxacin, norfloxacin, ofloxacin, orbifloxacin, pefloxacin, pipemidic acid, pradofloxacin, temafloxacin, tosufloxacin, sarafloxacin, sparfloxacin.
  • Penicillins, cephalosporins and related beta lactams such as amoxicillin, ampicillin, azidocillin, aztreonam, benzylpenicillin, cefaclor, cefadroxil, cefalexin, cefetamet, cefixime, cefodizime, cefotiam, cefpodoxime proxetil, cefsulodin, ceftibuten, ceftizoxime, cefuroxime, clavulanic acid, dicloxacillin, flucloxacillin , Imipenem, Loracarbef, Mezlocillin, Oxacillin, Phenoxymethylpenicillin, Propicillin, Sultamicillin, Tazobactam.
  • beta lactams such as amoxicillin, ampicillin, azidocillin, aztreonam, benzylpenicillin, cefaclor, cefadroxil, cefalexin, cefetamet, cefixime, ce
  • the analgesics aceclofenac, acemetacin, acetylsalicylic acid, buprenorphine, carprofen, celecoxib, codeine, deracoxib, diclofenac, dihydrocodeine, felbinac, fentanyl, flufenamic acid, flunixin, flupirtin, flurbiprofen, hydrofonolenoprofen, hydrofinophenol Mefenamic acid, meloxicam, metamizole, methadone, mofebutazone, morphine, naproxen, Nefopam, niflumic acid, oxaprozine, oxycodone, paracetamol, parecoxib, pentazocin, pethidine, phenazone, phenylbutazone, piroxicam, pietramide, proglumetacm, propyphenazone, rofecoxib, tepoxaline
  • the active ingredients 4-aminosaliylic acid, abacavir, abamectin, acamprosate, acebutolol, acepromazm, acetylcysteine, aciclovir, acitretin, adapalene, albendazole, alendronic acid, alfuzosin, alprostadil, aluminum chloride, aluminum oxide, amantadine, ambroodinol, ambroodinol, ambroxinol, ambroxinol, ambroodinol , ascorbic acid, atenolol, atorvastatin, Azithromycm, baclofen, Benazep ⁇ l, betamethasone, bezafibrate, bifonazole, Biotm, bisoprolol, B ⁇ vudm, Bromhexm, Bumetamd, bupranolol, calcium acetate, calcium carbonate, candesartan, Captop ⁇
  • the active substances mentioned can also be used in the form of their esters or salts, hydrates of the compounds are also included according to the invention.
  • Examples of pharmaceutically usable salts are the salts of hydrochloric acid, sulfuric acid, acetic acid, glycolic acid, lactic acid, succinic acid, citric acid, tartaric acid, maleic acid, methanesulfonic acid, 4-toluenesulfonic acid, galacturonic acid, gluconic acid, embonic acid, glutamic acid or aspartic acid.
  • compounds can be bound to acidic or basic ion exchangers.
  • the pharmaceutically usable basic salts are the alkali salts, for example the sodium or potassium salts, the alkaline earth salts, for example the magnesium or calcium salts; called the zinc salts, the silver salts and the guamdinium salts.
  • Hydrates mean both the hydrates of the free compounds themselves and the hydrates of their salts.
  • the active compounds can also be present in the preparations as a mixture with synergists or in combination with other active compounds. Examples
  • Figure 1 summarizes the plasma level after application of the examples according to the invention and compares it with the plasma level after oral administration of a tablet (dose 4 mg / kg body weight flupirtine maleate).
  • dose 4 mg / kg body weight flupirtine maleate the plasma level after oral administration of a tablet
  • Figure 2 the pharmacokmeti see data more comparable.
  • active substance concentrations in the plasma which correspond to those after oral administration of a tablet. Due to the delayed cleaning behavior after an operation, t, ⁇ is clearly shifted from 3-6 hours to 24 hours in this case. The maximum concentrations are also lower due to a delayed intake.
  • the application should take place a sufficient time before the operation so that the animal can still absorb therapeutically relevant amounts.
  • ponazuril 3.75 g of ponazuril are suspended in 44.25 g of glycerol and dispersed with a rotor-stator homogenizer. The result is 50 ml of a suspension with a ponazuril concentration of 7.5% M / M.
  • pradofloxacin 0.75 g of pradofloxacin are suspended in 49.25 g of polyethylene glycol 400 and dispersed with a rotor-stator homogenizer. The result is 50 ml of a suspension with a concentration of pradofloxacin of 1.5% M / M.
  • enrofloxacin 1.25 g of enrofloxacin are suspended in 48.75 g of medium-chain triglycerides (Miglyol 812) and dispersed with a rotor-stator homogenizer. The result is 50 ml of a suspension with a concentration of enrofloxacin of 2.5% M / M.
  • a volume corresponding to an enrofloxacin dose of approx. 5 mg / kg body weight was applied to a point in the area of the back line between the shoulder blades of 4 healthy cats. Blood samples were taken at the listed times and serum aliquots were examined by HPLC. Up to 4 hours after application, the animals wore a neck collar to prevent the application site from being licked / cleaned. The following serum concentrations of enrofloxacin and the active metabolite ciprofloxacin were obtained:
  • toltrazuril 7.5 g are suspended in 92.5 g of paraffin subliquidum and dispersed with a rotor-stator homogenizer. The result is 100 ml of a suspension with a concentration of toltrazuril of 7.5% M / M.
  • toltrazuril 4.0 g of toltrazuril are suspended in 96 g of sesame oil and dispersed with a rotor-stator homogenizer. The result is 100 ml of a suspension with a toltrazuril concentration of 4% M / M. A volume corresponding to a toltrazuril dose of approx. 15 mg / kg body weight was applied to a point in the area of the back line between the shoulder blades of 4 healthy cats. Blood samples were taken at the listed times and serum aliquots were examined by HPLC. Up to 4 hours after application, the animals wore a neck collar to prevent the application site from being licked. The following serum concentrations of toltrazuril and the active metabolite toltrazuril sulfone were obtained:
  • a volume corresponding to a toltrazuril dose of 8 mg / kg body weight was applied to a location in the area of the flank of 4 healthy rabbits. Blood samples were taken at the listed times and serum aliquots were examined by HPLC. Up to 4 hours after application, the animals were fixed in a forced device that prevented the application site from being licked. The following serum concentrations of toltrazuril and the active metabolite toltrazuril sulfone were obtained:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des préparations pharmaceutiques qui sont destinées à être appliquées sur les poils ou la peau d'animaux, de manière que ceux-ci puissent ensuite les absorber par voie orale.
EP05700727A 2004-01-10 2005-01-07 Medicament destine a etre administre a des animaux par voie topique Withdrawn EP1706097A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004001558A DE102004001558A1 (de) 2004-01-10 2004-01-10 Arzneimittel zur topischen Applikation bei Tieren
PCT/EP2005/000067 WO2005065713A2 (fr) 2004-01-10 2005-01-07 Medicament destine a etre administre a des animaux par voie topique

Publications (1)

Publication Number Publication Date
EP1706097A2 true EP1706097A2 (fr) 2006-10-04

Family

ID=34744661

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05700727A Withdrawn EP1706097A2 (fr) 2004-01-10 2005-01-07 Medicament destine a etre administre a des animaux par voie topique

Country Status (11)

Country Link
US (1) US20080255125A1 (fr)
EP (1) EP1706097A2 (fr)
JP (1) JP5704738B2 (fr)
AU (1) AU2005203884B2 (fr)
BR (1) BRPI0506753A (fr)
CA (1) CA2552909C (fr)
DE (1) DE102004001558A1 (fr)
NO (1) NO20063626L (fr)
NZ (1) NZ548422A (fr)
WO (1) WO2005065713A2 (fr)
ZA (1) ZA200605611B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005011779A1 (de) * 2005-03-11 2006-09-14 Bayer Healthcare Ag Endoparasitizide Mittel
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006038292A1 (de) * 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
DE102007055341A1 (de) 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
CN103315986B (zh) * 2013-05-24 2014-09-03 湖北龙翔药业有限公司 一种可溶且稳定的帕托珠利组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402941A (en) * 1981-09-15 1983-09-06 Marc Vaillancourt Veterinary composition for preventing feline urological syndrome and litter product containing the composition
IN172468B (fr) * 1990-07-14 1993-08-14 Asta Medica Ag
US5122377A (en) * 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
NZ256788A (en) * 1992-09-30 1996-11-26 Cornell Res Foundation Inc Conferring resistance to fire blight in pomaceous fruit scion or cultivars through transformation with genes encoding lytic proteins
NZ332719A (en) * 1996-05-10 2000-01-28 Upjohn Co Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
DE19824483A1 (de) * 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
WO2000019964A2 (fr) * 1998-10-08 2000-04-13 New Ace Research Company Nouvelles compositions et nouveaux procedes destines a la prevention et au traitement de maladies provoquees par des protozoaires
US6150361A (en) * 1998-12-22 2000-11-21 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
WO2000074714A2 (fr) * 1999-06-03 2000-12-14 Glenn Gregory M Indicateurs de controle de la technique d'immunisation transcutanee
RU2002105502A (ru) * 1999-08-03 2004-03-20 АВД.фарма ГмбХ унд Ко. КГ (DE) Применение флупиртина для облегчения болей, вызванных дегенеративными заболеваниями суставов у собак и кошек
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE602004009664D1 (de) * 2003-01-16 2007-12-06 Janssen Pharmaceutica Nv Diclazurilhaltige antiprotozoenmittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005065713A2 *

Also Published As

Publication number Publication date
JP2007519637A (ja) 2007-07-19
BRPI0506753A (pt) 2007-05-22
JP5704738B2 (ja) 2015-04-22
NO20063626L (no) 2006-10-10
CA2552909A1 (fr) 2005-07-21
ZA200605611B (en) 2007-11-28
NZ548422A (en) 2010-04-30
AU2005203884B2 (en) 2011-04-14
WO2005065713A2 (fr) 2005-07-21
AU2005203884A1 (en) 2005-07-21
DE102004001558A1 (de) 2005-08-18
US20080255125A1 (en) 2008-10-16
CA2552909C (fr) 2014-05-27
WO2005065713A3 (fr) 2006-05-11

Similar Documents

Publication Publication Date Title
CN102639131A (zh) 舌下右美托咪定组合物及其使用方法
EP1419774A1 (fr) Composition pharmaceutique de morphine pour administration intranasale
DE60307258T2 (de) Salze von Tolterodin
WO2018114503A1 (fr) Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires
EP3558380A1 (fr) Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires
WO2003101422A2 (fr) Preparations pharmaceutiques pour administration orale, contenant des resines echangeuses d'ions chargees de principes actifs ainsi que des gelifiants a viscosite intrinseque comme epaississants
US20240374516A1 (en) Ready to use oral pharmaceutical suspension of dasatinib
TW201705960A (zh) 癸二醯雙那布扶林酯之緩釋藥物製劑
CH662734A5 (de) Antischnarchmittel.
WO2005065713A2 (fr) Medicament destine a etre administre a des animaux par voie topique
EP3796907A1 (fr) Composés modulateurs allostériques positifs gabaa pour le traitement du prurit et/ou de la dermatite
EP1337254B1 (fr) Utilisation d'opioides faibles et d'agonistes/d'antagonistes opioides melanges pour traiter l'incontinence urinaire
EP1368023B1 (fr) Utilisation de buprenorphine pour traiter l'incontinence d'urine
BR112019018700A2 (pt) composições farmacêuticas e seus usos
DE10338544A1 (de) Buccale Formulierungen des Galanthamins und deren Anwendungen
DE202021100040U1 (de) Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
WO2007022609A1 (fr) Composition pharmaceutique de morphine sous forme de solution injectable prete a l'emploi et forme posologique unitaire de morphine pour administration epidurale ou intrathecale
MXPA06007717A (en) Topically applied medicament for animals
EP3338764A1 (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
DE3810350A1 (de) Dhp-retard-zubereitung
TR201808806A2 (tr) Deksketoprofen, parasetamol ve feni̇lefri̇n i̇çeren farmasöti̇k kompozi̇syonlar
DE102016008547A1 (de) Oromukosale Verabreichung von Robenacoxib bei Tieren
EP3338803A1 (fr) Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires
HK1062812A (en) Pharmaceutical formulations and methods comprising intranasal morphine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17P Request for examination filed

Effective date: 20061113

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER ANIMAL HEALTH GMBH

17Q First examination report despatched

Effective date: 20090428

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160819